Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events ...
AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
Clinical Trials Arena on MSN
Ipsen’s ultra-rare bone disease drug flops in Phase II trial
Ipsen’s failure comes shortly after Regeneron’s FOP study met its endpoints, sparking an FDA approval submission.
By a News Reporter-Staff News Editor at Disease Prevention Daily-- A new study on Drugs and Therapies- Kinase Inhibitors is now available. Financial supporters for this research include Taiju Life ...
Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results